RxDoctor Payments Data

Robert Jackson, MD

Urology · Boise, IDNPI 1184740045

Payments from drug & device makers

What this record shows

This record is dominated by education: $6,004 of the $7,087 with a category attached, or 84.7%. Intuitive Surgical accounts for 84.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $6,271 and has fallen 95.2% since, to $304 in 2025.

$7,087in general payments, 2019–2025

Across 46 payments — averaging $154.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Medtronic$300
  • Boston Scientific$276
  • Astellas Pharma US Inc$163
  • AbbVie$90
  • Ferring Pharmaceuticals Inc.$48
  • plus $212 from 9 others

What the payments were for

  • Food & beverage$1,08415%
  • Education$6,00485%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,087 in reported general payments places this provider in the 85th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$88,162
Medicare patients
374
Services billed
921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron42$38,179
GemtesaVibegron35$32,914
Testosterone44$11,488
Tamsulosin Hcl443$6,509
Silodosin56$4,633
Testosterone Cypionate79$3,433
Finasteride182$2,349
Trospium Chloride ErTrospium Chloride15$2,303
Potassium Citrate ErPotassium Citrate17$2,260
Alfuzosin Hcl ErAlfuzosin Hcl81$1,267
Cefdinir34$595
Oxybutynin Chloride ErOxybutynin Chloride16$530
Terazosin Hcl20$423
Tadalafil12$290
Cephalexin24$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$163$38,17942 claims
Sumitomo Pharma America, Inc.Gemtesa$27$32,91435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 urology providers in Idaho.

Other urology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →